Observational findings demonstrate efficacy and safety of somatrogon in children with growth hormone deficiency, suggesting a viable alternative to daily treatments.
Once-weekly somatrogon demonstrated efficacy and safety comparable to daily somatropin with stable quality of life and psychosocial outcomes in children with GHD.
No takes yet. Share an insight, caveat, or question.
Küçük et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: